A clinical trial by National Institutes of Health, evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with Covid-19, has concluded that the drug provides no clinical benefit to hospitalised patients.
Early findings the trial indicated that the drug was not improving outcomes in Covid-19 patients. Final data and analyses of the trial was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH.
Titled Outcomes Related to Covid-19 treated with Hydroxychloroquine among Inpatients with symptomatic Disease (ORCHID), the trial began after lab studies and preliminary reports suggested that hydroxychloroquine — commonly used to treat malaria and rheumatic conditions like arthritis — might have promise in treating SARS-CoV-2, the virus that causes Covid-19.
Preliminary evidence
The Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network of NHLBI started the trial in April at 34 hospitals across the United States and enrolled 479 of the expected 510 patients. By June, preliminary evidence indicated hydroxychloroquine was unlikely to offer any benefit.
According to NIH officials, the careful design, implementation, and oversight of the study was key to its results, as well as the recommendation by a data and safety monitoring board (DSMB) to stop the trial early.
James P. Kiley, Ph.D., director, Division of Lung Diseases at NHLBI, said, “Having a rigorously designed clinical trial that captured patient-centered, clinically meaningful outcomes was critical to reaching the unequivocal conclusions about the use of hydroxychloroquine in COVID-19. ORCHID shows that hydroxychloroquine does not improve clinical outcomes in hospitalized Covid-19 patients.”
He added that they hope this clear result will help practitioners make informed treatment decisions and researchers continue their efforts pursuing other possible safe and effective treatments for patients suffering with this disease.
The ORCHID trial enrolled participants between April 2 and June 19 who were a median age of 57. They included 290 Hispanic and Black participants and 212 female participants. All participants received clinical care as indicated for their condition. Participants were randomly assigned to a treatment group and received 10 doses of either hydroxychloroquine or a placebo over five days.
Scientists then assessed each patient’s clinical status 14 days after being assigned to a treatment group. They used a seven-category scale ranging from one (death) to seven (discharged from the hospital and able to perform normal activities).
Researchers also measured 12 additional outcomes, including death that occurred 28 days after the participants’ assignment to a treatment group.
![](https://theonlook.com/wp-content/uploads/2023/10/For-wordpress.jpg")
On day 14, those who received hydroxychloroquine and those who received a placebo had a similar health status, with most participants in both groups discharged from the hospital and able to perform a range of activities.
The number of participants in both treatment groups who died at day 14 was also similar. At day 28, 25 of 241 patients in the hydroxychloroquine group and 25 of 236 patients in the placebo group had died.
The ORCHID trial was funded by NIH/NHLBI grants 3 U01 HL123009-06S1, U01HL123009, U01HL122998, U01HL123018, U01HL123023, U01HL123008, U01HL123031, U01HL123004, U01HL123027, U01HL123010, U01HL123033, U01HL122989, U01HL123022, and U01HL123020. The study was also supported by the National Center for Advancing Translational Sciences Awards UL1TR001102 and UL1TR002541.
(With inputs from The OnLook News Research Bureau)
If you like this article and if you feel it will be helpful for others to understand on the subject, please share it. You can also follow us on Twitter, Facebook & Linkedin
Also read: Pfizer, Biontech announce vaccine candidate against Covid-19
